Vivimed Labs Limited (BOM:532660)

India · Delayed Price · Currency is INR

5.93

-0.16 (-2.63%)

At close: Jun 19, 2026

-78.75% (1Y)

Market Cap	490.85M -43.6%
Revenue (ttm)	883.92M -35.5%
Net Income	-349.49M
EPS	-4.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,658
Open	6.09
Previous Close	6.09
Day's Range	5.90 - 6.12
52-Week Range	5.15 - 27.99
Beta	n/a
Analysts	Hold
Price Target	142.00 (+2,294.6%)
Earnings Date	May 30, 2026

About Vivimed Labs

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups ... [Read more]

Industry Chemicals and Allied Products

Founded 1988

Employees 586

Stock Exchange Bombay Stock Exchange

Ticker Symbol 532660

Full Company Profile

Financial Performance

In fiscal year 2025, Vivimed Labs's revenue was 1.21 billion, a decrease of -24.15% compared to the previous year's 1.59 billion. Losses were -319.61 million, -29.67% less than in 2024.

Financial Statements